Cantor Fitzgerald Reiterates “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They currently have a $128.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential downside of 4.23% from the company’s current price.

Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $166.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. UBS Group raised their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Mizuho raised their price objective on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Evercore ISI raised their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $160.60.

Sarepta Therapeutics Trading Up 2.3 %

NASDAQ SRPT traded up $3.03 on Thursday, hitting $133.66. The company’s stock had a trading volume of 1,196,284 shares, compared to its average volume of 876,130. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a current ratio of 4.05, a quick ratio of 3.45 and a debt-to-equity ratio of 1.18. The company’s 50-day simple moving average is $125.63 and its 200 day simple moving average is $110.81. The firm has a market cap of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter last year, the business posted ($1.44) EPS. The business’s revenue was up 63.1% on a year-over-year basis. Research analysts predict that Sarepta Therapeutics will post 2.14 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,096 shares of company stock worth $2,739,419. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Principal Securities Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter valued at about $26,000. Mather Group LLC. bought a new stake in Sarepta Therapeutics during the first quarter valued at about $28,000. Riggs Asset Managment Co. Inc. increased its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Montag A & Associates Inc. bought a new stake in shares of Sarepta Therapeutics in the third quarter worth about $30,000. Finally, Cary Street Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.